Pick the drugs you want to compare.
Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.
Drug 1
Drug 2
Drug 3 (optional)
Drug 4 (optional)
Side by side, line by line.
Compare across
11 dimensions
Central alpha-2 Adrenergic Agonist
Dexmedetomidine
Brand: Dexmedetomidine Hydrochloride in Sodium Chloride
First FDA approval:
Lowest NADACAcquisition cost floor across all NDCs
—Per unit
$0.140Per unit
Average NADACAcross all dosage forms and strengths
—
$0.740Up to $9.31
Generic manufacturersActive ANDA holders — FDA Orange Book
2449 total ANDAs filed
1860 total ANDAs filed
Annualized Part D spendCY2024 — CMS Part D Spending Dashboard
$308999Full year
$14.4MFull year
Part D claims (CY24)Total fills, all strengths
9742 beneficiaries
398K89K beneficiaries
Avg cost per claimCalculated: total spend ÷ total claims
$3,186Per claim, all NDCs
$36Per claim, all NDCs
Part D plans surveyed2026 plan year — CMS Formulary file
329Across CMS plan year
329Across CMS plan year
Prior-authorization frictionPlan-NDC pairs requiring PA
—Zero PA friction
412Substantial friction
Step therapy appliedPlan-NDC pairs requiring step therapy
—None
0None
FDA shortage statusLive cross-reference vs FDA Drug Shortage Database
Active shortageSee drug profile
DiscontinuedSee drug profile
Generic availableFDA Orange Book
Yes24 manufacturers
Yes18 manufacturers